Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade ...

REPL

<p>口头报告的生物标志物数据显示，RP1 联合 nivolumab 在经过明确的抗 PD-1 治疗失败后，能够逆转晚期黑色素瘤中多种对 PD-1 阻断的耐药机制</p>

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer  ( SITC 2025 ) 

Replimune 在第 40 届癌症免疫治疗学会年会上展示 RP1 的最新突破性摘要和其他海报